Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-BCX in Relapsed/Refractory Multiple Myeloma
NCT04601935Phase 1Unknown
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-BCX in multiple myeloma (MM). Primary endpoint: Number of Participants With Adverse Events at 30 days. Status: unknown.
02
Drugs
LCAR-BCX
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04601935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601935.